Physician profile
Benjamin C Moore
NPI 1518131754
$2,196.18
in general payments reported to CMS, 2019-2025
27 companies · $432 in 2025
The $432 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $107 · 2021: $346 · 2022: $311 · 2023: $403 · 2024: $245 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.93 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.38 | 2019-2023 | |
| Astellas Pharma US INC | $277.34 | 2019-2025 | Veozah, Myrbetriq |
| Organon LLC | $245.70 | 2022-2025 | Nexplanon, Jada System |
| Mayne Pharma Commercial LLC | $223.17 | 2022-2025 | |
| Hologic Sales and Service, LLC | $174.05 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Daiichi Sankyo INC. | $96.90 | 2019-2024 | Injectafer |
| Sumitomo Pharma America, INC. | $82.38 | 2023-2025 | Gemtesa, Myfembree |
| Boston Scientific Corporation | $72.10 | 2019-2025 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $70.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $69.32 | 2019-2023 | Gardasil 9 |
| Amgen INC. | $59.57 | 2019-2024 | Prolia, Evenity |
| Coopersurgical, INC. | $53.85 | 2019-2021 | |
| Stryker Corporation | $42.96 | 2021 | |
| Lupin INC. | $39.37 | 2019-2020 | |
| Sage Therapeutics, LLC | $35.27 | 2025 | Zurzuvae |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $35.27 | 2025 | Qelbree |
| Duchesnay USA Incorporated | $34.17 | 2019 | |
| Therapeuticsmd, INC. | $28.43 | 2019 | |
| Agile Therapeutics, INC. | $23.44 | 2022 | |
| Millicent US INC | $17.84 | 2024 | Intrarosa, Femring |
| Baxter Healthcare | $17.31 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $16.37 | 2025 | |
| Gilead Sciences, INC. | $16.27 | 2019 | |
| Meditrina | $15.23 | 2022 | |
| Minerva Surgical, INC | $14.62 | 2024 | |
| Axonics, INC. | $13.86 | 2021 | |
| Pfizer INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.